RU94039254A - Method for controlling physiologic state of the organism in gerontological period of ontogenesis - Google Patents

Method for controlling physiologic state of the organism in gerontological period of ontogenesis

Info

Publication number
RU94039254A
RU94039254A RU94039254/14A RU94039254A RU94039254A RU 94039254 A RU94039254 A RU 94039254A RU 94039254/14 A RU94039254/14 A RU 94039254/14A RU 94039254 A RU94039254 A RU 94039254A RU 94039254 A RU94039254 A RU 94039254A
Authority
RU
Russia
Prior art keywords
ontogenesis
period
gerontological
organism
physiologic state
Prior art date
Application number
RU94039254/14A
Other languages
Russian (ru)
Inventor
Б.Н. Доценко
Original Assignee
Б.Н. Доценко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Б.Н. Доценко filed Critical Б.Н. Доценко
Priority to RU94039254/14A priority Critical patent/RU94039254A/en
Publication of RU94039254A publication Critical patent/RU94039254A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

FIELD: medicine. SUBSTANCE: method involves reducing neurohormonal receptor surface in optimum way by means of prosthetic repair. EFFECT: enhanced effectiveness of method.

Claims (1)

В основе изобретения физиологическое состояние геронтологического периода онтогенеза, которое отличается от других периодов тем, что в этом периоде сокращается нервногармональная рецепторная поверхность. С целью продления экономически активного времени онтогенеза осуществляется оптимальное сокращение рецепторной поверхности с помощью протезирования.The basis of the invention is the physiological state of the gerontological period of ontogenesis, which differs from other periods in that the nervous harmonic receptor surface is reduced in this period. In order to extend the economically active time of ontogenesis, the optimal reduction of the receptor surface by means of prosthetics is carried out.
RU94039254/14A 1994-10-18 1994-10-18 Method for controlling physiologic state of the organism in gerontological period of ontogenesis RU94039254A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94039254/14A RU94039254A (en) 1994-10-18 1994-10-18 Method for controlling physiologic state of the organism in gerontological period of ontogenesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94039254/14A RU94039254A (en) 1994-10-18 1994-10-18 Method for controlling physiologic state of the organism in gerontological period of ontogenesis

Publications (1)

Publication Number Publication Date
RU94039254A true RU94039254A (en) 1996-09-20

Family

ID=48449644

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94039254/14A RU94039254A (en) 1994-10-18 1994-10-18 Method for controlling physiologic state of the organism in gerontological period of ontogenesis

Country Status (1)

Country Link
RU (1) RU94039254A (en)

Similar Documents

Publication Publication Date Title
DE60042137D1 (en) RECOMBINANT ALPHA-L-IDURONIDASE AND TREATMENT OF SUFFERED SKIN DISEASES
DE69839815D1 (en) USE OF PPAR-GAMMA ACTIVATORS FOR THE TREATMENT OF SKIN DISEASES
DE69616376D1 (en) Use of tiagabin for the treatment of sleep disorders
AU2267192A (en) Treatment of migraine by nerve stimulation
HUP9603484A2 (en) Pharmaceutical compositions and process for producing symptom-transduction
AU7467496A (en) Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
DE69731540D1 (en) TREATMENT OF DIARRHOE
ATE226091T1 (en) CONTROLLED RELEASE MICROCAPSULES AND THEIR USE FOR STIMULATING NERVE FIBER GROWTH
PL328800A1 (en) Novel bridge-type cyclic amino acids as pharmaceutic agents
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
DE69632236D1 (en) USE OF DHA IN THE TREATMENT OF DYSLEXIA
ATE218336T1 (en) USE OF 3-BENZOYLPHENYLACETIC ACIDS, THEIR ESTERS OR AMIDES FOR THE TREATMENT OF GLC1A GLAUCOMA
FR2760369B1 (en) MULTI-SITE HEART STIMULATOR FOR THE TREATMENT OF HEART FAILURE BY STIMULATION
DE69530933D1 (en) USE OF 5- (TETRADECYLOXY) -2-FURANIC CARBONIC ACID FOR THE TREATMENT OF ALZHEIMER DISEASE OR PSYCHOSIS
AU2173400A (en) Method for administering agents to the central nervous system
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
DE69819110D1 (en) A medicine to treat obesity and improve lipid metabolism
BR0010183A (en) Monofluoroalkyl derivatives
BG102064A (en) Method for increasing the retinal blood circulation
MX9701187A (en) Novel n-substituted naphthofused lactams.
DE60016181D1 (en) C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
TR199900527T2 (en) Use of benzopyranols for the treatment of neurological disorders.
RU94039254A (en) Method for controlling physiologic state of the organism in gerontological period of ontogenesis
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue